Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cycloplegic regimen effects on ocular and systemic parameters in children with refractive error
ISRCTN17363525Phase 3Completed
- Sponsor
- Cicendo National Eye Hospital
- Start
- Nov 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of cyclopentolate, tropicamide and phenylephrine in ametropia (2 arms), sponsored by Cicendo National Eye Hospital. Primary endpoints: Refractive power at 60 minutes and Pupil diameter at 60 minutes. Started Nov 2020; status: completed.
02
Drugs
cyclopentolatetropicamidephenylephrine
03
Conditions
ametropia
Beyond the preview
Go deeper on ISRCTN17363525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17363525.